Holen Sie sich die Stockscreener-App
24.31
0.79%
0.19
Handel nachbörslich:
23.83
-0.48
-1.97%
Schlusskurs vom Vortag:
$24.12
Offen:
$24.5
24-Stunden-Volumen:
2.31M
Relative Volume:
1.97
Marktkapitalisierung:
$3.06B
Einnahmen:
$236.00M
Nettoeinkommen (Verlust:
$-369.00M
KGV:
-7.6379
EPS:
-3.1828
Netto-Cashflow:
$-489.00M
1W Leistung:
+4.33%
1M Leistung:
+3.89%
6M Leistung:
+10.55%
1J Leistung:
+185.66%
1-Tages-Spanne:
$23.80
$24.84
1-Wochen-Bereich:
$23.27
$24.84
52-Wochen-Spanne:
$7.91
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
24.31 | 3.06B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Arcus Biosciences Inc (RCUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcus Biosciences Inc (RCUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcus Biosciences Inc (RCUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
(RCUS) Risk Channels and Responsive Allocation - Stock Traders Daily
Arcus, Bristol Myers team up to advance kidney cancer study - MSN
Arcus Biosciences Stockholders Back Directors and Governance Measures - The Globe and Mail
Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options - Stock Titan
Arcus Biosciences (RCUS) grants director RSUs and stock options - Stock Titan
Arcus Biosciences (RCUS) director receives RSU and stock option awards - Stock Titan
Arcus Biosciences counsel exercises 34,090 options | RCUS Insider Trading - Stock Titan
Director David L. Lacey receives RCUS stock awards at Arcus Biosciences (RCUS) - Stock Titan
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences (RCUS) director Antoni Ribas receives RSU and option awards - Stock Titan
Arcus Biosciences (RCUS) director receives new RSU and stock option grants - Stock Titan
Arcus Biosciences (NYSE: RCUS) reports 2026 shareholder vote results - Stock Titan
Arcus Biosciences Jumps 6.9% Amid Sector-Wide Rally - AlphaStreet
Arcus Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus Biosciences Drops 7.0% After LifeSci Capital Initiates at Outperform - AlphaStreet
What Did Arcus Biosciences Highlight at the Goldman Sachs Healthcare Conference - Kavout
New hire at Arcus Biosciences gets stock options and RSUs - Stock Titan
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow (NYSE:RCUS) 2026-06-09 - Seeking Alpha
Arcus Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $36.73, Implies 58% Upside - TradingView
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
(RCUS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness - Sahm
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Biosciences (RCUS) Earnings Date and Reports 2026 - MarketBeat
Arcus Biosciences Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
RCUS Initiated Coverage by LifeSci Capital -- Rating Set to Outp - GuruFocus
Lifesci Capital Initiates Coverage on Arcus Biosciences (NYSE:RCUS) - MarketBeat
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating - Moomoo
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment - marketscreener.com
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial - marketscreener.com
New drug combo from Arcus and BMS targets advanced kidney cancer - Stock Titan
Arcus Biosciences Drops 6.0% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences chief accounting officer sells $66,023 in stock By Investing.com - Investing.com South Africa
Arcus Biosciences chief accounting officer sells $66,023 in stock - Investing.com
Arcus Biosciences (RCUS) CAO 10b5-1 sale of 2,562 shares - Stock Titan
[144] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences (RCUS) Surges 3.6%: Can the Breakout Hold Above Key Resistance?getLinesFromResByArray error: size == 0 - lwvtexas.org
Biotech Catalysts Put Three Small Caps On Watch - Kalkine Media
RCUS Stock Price, Quote & Chart | ARCUS BIOSCIENCES INC (NYSE:RCUS) - ChartMill
Arcus Biosciences joins Goldman Sachs chat, offers live webcast June 9 - Stock Titan
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Liquidity Mapping Around (RCUS) Price Events - Stock Traders Daily
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):